Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Completed · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Atorvastatin calcium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atorvastatin calcium together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving atorvastatin calcium together with celecoxib works in treating patients with rising PSA levels after local therapy for prostate cancer.
Key facts
- Study ID
- NCT01220973
- Run by
- Rutgers, The State University of New Jersey
- People needed
- 27
- Starts
- 2009-02-01
- Expected to finish
- 2014-11-18
- Last updated by the study team
- 2018-06-08
Who can join
Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Karmanos Cancer Center — Detroit, Michigan, United States
- Cooper Hospital — Camden, New Jersey, United States
- Robert Wood Johnson University Hospital at Hamilton — Hamilton, New Jersey, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.